Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quantum BioPharma Ltd C.HUGE


Primary Symbol: C.QNTM Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.


CSE:QNTM - Post by User

Comment by Mil_Man54on Sep 28, 2021 4:40pm
34 Views
Post# 33932102

RE:RE:RE:Question for GrahamB, Reno, or Walter

RE:RE:RE:Question for GrahamB, Reno, or WalterTryN2Learn.....GrahamB is really one of the guys you want to pay attention to on this board when he posts......his post history is well worth your time to look at if you want the straight story on FSD.....

GrahamB wrote:
DavidRosenberg wrote:

 

TryN2Learn wrote: Would any of you be able to answer the question:

"there was the issuance of 4,502,392 Class B Subordinate voting shares in the capital of FSD Pharma".... Does this mean that FSD Pharma created these shares in order to purchase Lucid? Any feedback from anybody would be greatly appreciated, thank you in advance.

 

 


yes these shares were created and given as part of the deal to accuire lucid 

4.5m shares is nothing compared to what previous management did from 7.89m shares to 36m shares 

 


 

 


David 
Seriously 
Do you remember all the shares Anthony and crew received in the past -and he was part of the management!

Here are a few little facts from the past :
 

FSD Pharma Issues $5.2 Million Worth Of Shares To Management As Compensation

 

 

On Monday, the company filed a notice of issuance of listed securities form with the Canadian Securities Exchange, indicating $5.2 million worth of shares had been issued by the company. The kicker, is that the issuance was directly to the firms executive team.

The notice of the share issuance was discreetly listed at the bottom of a July 31, 2020 news released filed by the company, in connection with a US $10 million registered direct offering. At the time, 1,322,927 Class B common shares of the issuer were to be issued to its directors and management team as compensation. That figure however climbed to 1,692,182 Class B common shares by the date of issuance – growing the firms share count by 15.7% in the process.

The largest distribution went to the firms CEO, Raza Bokhari, whom received 805,802 shares in total, or roughly half of the issuance, at a deemed price of $3.1025, the equivalent of $2.5 million. Issuance’s to other members of management was rather sporadic, with some directors and executives not receiving any shares at all.

Each of Edward Brennan, Steve Buyer, Donal Carroll, Robert Claruffoli and David Urban received 80,580 shares in the issuance, while Zeeshan Saeed and Anthony Durkacz received 161,160 shares. Director Gerry Goldberg received the smallest issuance, at 32,232 shares.

 

 

https://thedeepdive.ca/fsd-pharma-issues-5-2-million-worth-of-shares-to-management-as-compensation/

 

 

It seems you either have no insight ,obscure, or don’t care that you lack a basic understandiing of financial statements, the mechanics of investing, and the truth of FSD.

We also remember when you told the board you were also offered shares for your work in the board


 



<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse